Rentschler Biopharma SE has appointed Detra Glinatsis as Head of Business Development U.S., where she will lead all business development activities related to the U.S. market.

She reports to Dr. Patrick Meyer, Global Head of Business Development, and is based at the company’s site in Milford, MA.

“I am excited to have Detra rejoin Rentschler Biopharma to serve in this important role,” remarked Patrick Meyer. “Her career is a true testament to her expertise, client‑centric mindset, and ability to build long‑lasting, meaningful partnerships.”

Experience

Detra Glinatsis brings over twenty years of sales and business development experience in the pharmaceutical, biotech and contract manufacturing industries. She rejoins Rentschler Biopharma from Northway Biotech, where she was Vice President, Business Development.

Glinatsis previously held roles of increasing responsibility at AGC Biologics, Sartorius, Gallus BioPharmaceuticals, and Avecia Biologics, as well as Rentschler Biopharma. She holds a B.S. in biology from the University of Akron.

“I am thrilled to come back to Rentschler Biopharma as the company continues to grow its U.S. business,” Glinatsis said. “Together with the team, I look forward to building on the success that the company has achieved with the Milford site expansion and continuing to enhance the Rentschler Biopharma brand in the U.S. The company has a long-standing reputation for top quality and reliability, and I am excited to be working with such a talented team with a coveted track record.”

More Rentschler News

Earlier this month, Rentschler Biopharma and VarmX, a biotech company, entered a collaboration for the manufacture VarmX’s lead program, VMX-C001, for Phase 3 development and potential commercialization.